Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639330 | 0.80 | ELANE (0.34) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL4494018 | 0.79 | TDP1 (0.39) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL697015 | 0.77 | — | — | |
| SCHEMBL5539990 | 0.77 | HDAC6 (0.38) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL29121 | 0.76 | DGAT1 (0.46) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL12604849 | 0.75 | ELANE (0.34) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| Ammonia Solution, Strong SCHEMBL9998492 | 0.74 | DGAT1 (0.43) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| Hydrogen Peroxide SCHEMBL28079587 | 0.74 | DGAT1 (0.43) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| Fluoride SCHEMBL2692246 | 0.74 | DGAT1 (0.43) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| Methyl Alcohol SCHEMBL28820308 | 0.74 | DGAT1 (0.43) | ELANEDGAT1HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711010-B2 | Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2020-07-14 | — | — | US | claimed |
| US-20180170947-A1 | HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2018-06-21 | — | — | US | claimed |
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | claimed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| WO-2004046153-A1 | PRODRUG ESTERS OF CEFTRIAXONE | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| US-6185453-B1 | IONTOPHORETIC DEVICE INCLUDING SPECIFIED INTEGRIN INHIBITORS SUCH AS N3-(2-(3-(4-FORMAMIDINOPHENYL)-ISOXAZOLIN-5(R,S)-YL)-ACETYL)-N2 -(PHENYLSULFONYL)-2,3-(S)-DIAMINOPROPANOIC ACID | DUPONT PHARMACEUTICALS COMPANY | 2001-02-06 | — | — | US | claimed |
| EP-0730590-B1 | ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-01-17 | — | — | EP | claimed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | claimed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | claimed |
| EP-0370454-B1 | Renin-inhibiting amino diol derivatives | HOECHST AG (DE) | 1994-04-20 | — | — | EP | claimed |
| EP-0370454-A2 | Renin-inhibiting amino diol derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | claimed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | claimed |
| US-4376770-A | OXACEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1983-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170947-A1 | HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CASP3, BAX, CASP7 | ELANE 820/4885DGAT1 4484/4885HDAC6 1662/4885 |
| US-10711010-B2 | Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | CASP3, BAX, CASP7 | ELANE 820/4885DGAT1 4484/4885HDAC6 1662/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | ELANE 63/4885DGAT1 3823/4885HDAC6 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.